Table 1.
The cutoff value and diagnostic ability of each fibrosis marker in NAFLD patients.
| NAFLD (n = 58) | |||||
|---|---|---|---|---|---|
| Fibrosis Markers | Cutoff | AUROC | Sensitivity | Specificity | |
| WFA+-M2BP | C.O.I | 1.06 | 0.70 | 75 | 67 |
| TIMP-1 | ng/mL | 242.0 | 0.50 | 50 | 68 |
| HA | ng/mL | 58.9 | 0.87 | 80 | 86 |
| PIIIP | ng/mL | 11.4 | 0.58 | 50 | 74 |
| Platelet count | ×104/μL | 17.7 | 0.74 | 67 | 80 |
| FIB-4 Index | – | 1.95 | 0.77 | 67 | 78 |
| APRI | – | 3.25 | 0.62 | 50 | 70 |
| AST/ALT ratio | – | 0.82 | 0.75 | 75 | 78 |
| ICG-R15 | % | 10.5 | 0.74 | 67 | 64 |
Stage 0–2 (n = 46) vs. Stage 3–4 (n = 12). AUROC, area under the receiver operating characteristic curve; NAFLD: nonalcoholic fatty liver disease.